Cell Therapeutics vor Tounaround?

Aktien der Serie 2 Vorzugsaktien erhalten Dividenden in der gleichen Höhe wie alle angemeldeten und gezahlten Dividenden auf Aktien der Stammaktien und haben kein Stimmrecht zu allgemeinen Gesellschaftsrecht.

Die Schließung des Angebots ist zu erwarten am 24. August 2009, zu welchem Zeitpunkt die Gesellschaft erhalten die Cash-Erträge liefern und die Wertpapiere.

Rodman & Renshaw, LLC, eine hundertprozentige Tochtergesellschaft von Rodman & Renshaw Capital Group, Inc., als die ausschließliche Vermittler für das Angebot.

Ein Regal Registrierungserklärung in Bezug auf die Aktien der Serie 2 Vorzugsaktien und Optionsscheine, die im Angebot (und die Aktien von Stammaktien issuable auf Umwandlung der Vorzugsaktien der Serie 2 und Ausübung der Optionsscheine) wurde bei der Securities and Exchange Commission (die "SEC"). Die Globalregistrierung wurde automatisch wirksam, sobald die Einreichung bei der SEC. Ein Prospekt Ergänzung für das Angebot wird bei der SEC. Kopien des Prospekts zu ergänzen und begleiten und die Prospekt kann direkt von der Firma durch die Kontaktaufnahme mit dem Unternehmen unter der folgenden Adresse: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. Diese Bekanntmachung ist weder ein Angebot zum Verkauf noch eine Aufforderung zur Abgabe eines Angebots zum Kauf einer Aktie der Serie 2 Preferred Stock oder Optionsscheine. Kein Angebot, Aufforderung oder der Verkauf wird in jedem Land, in dem ein solches Angebot, Aufforderung oder Verkauf rechtswidrig ist.

Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die eine Reihe von Risiken und Unsicherheiten, die Ergebnisse, die wesentlich und / oder nachteilig auf tatsächliche zukünftige Ergebnisse und der Handel die Preise von Wertpapieren des Unternehmens. Die Risiken und Unsicherheiten beinhalten das Risiko, dass der Anleger unter Umständen nicht Ausübung ihrer Optionsscheine, die Gesellschaft möglicherweise nicht in der Lage, zusätzliches Kapital bei Bedarf zur Finanzierung ihrer Tätigkeit, der Gesellschaft die Absichten in Bezug auf die Verwendung der Erträge und andere Risikofaktoren zu finden oder beschrieben, von Zeit zu Zeit in der Gesellschaft Filings bei der SEC, einschließlich, ohne Einschränkung, ihre jüngsten Anmeldungen auf Formulare 10-K, 10-Q und 8-K. Außer dies ist gesetzlich vorgeschrieben, das Unternehmen hat nicht die Absicht zu aktualisieren, der in dieser Pressemitteilung enthaltene Aussagen, auf die weitere Entwicklung.

Medien-Kontakt: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: media@ctiseattle.com www.celltherapeutics.com/press_room Investoren Kontakt: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T: 206,272. 4347 F: 206.272.4434 E: invest@ctiseattle.com www.celltherapeutics.com/investors

Cell Therapeutics, Inc.

KONTAKT: Medien, Dan Eramian, +1-206-272-4343, Handy, +1-206-854-1200,
media@ctiseattle.com, oder Investoren, Ed Bell, +1-206-272-4345, oder Lindsey Jesch
Logan, +1-206-272-4347, Fax, +1-206-272-4434, invest@ctiseattle.com, alle
Cell Therapeutics, Inc.

Web-Site: www.celltherapeutics.com/


© 2009 PR Newswire

und es geht wieder runter...

FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone
finance.yahoo.com/news/...-prnews-2877889483.html?x=0&.v=1

Pixantrone (BBR 2778), ist ein neues Topoisomerase II-Inhibitor mit einem aza-anthracendion molekularen Struktur, die es derzeit auf dem Markt von Anthrazykline und verwandte Chemotherapeutika unterscheidet. Anthrazykline sind die Eckpfeiler für die therapeutische Behandlung von Lymphomen, Leukämien und Brustkrebs. Obwohl Anthrazykline ausreichend wirksam sind, als erstes verwendet werden-line (Erst-) Behandlung, Anthrazykline Ursache kumulativen Herzschäden führen, dass Herzinsuffizienz viele Jahre später kann. Als Ergebnis gibt es einen zeitlichen Begrenzung der Anthrazyklin-Dosen und die meisten Patienten, die zuvor mit einem Anthrazyklin behandelt wurden, sind nicht in der Lage, weitere Anthrazyklin-Behandlung erhalten, wenn der Patient die Krankheit gibt.  Pixantrone auch über eine periphere Vene statt einer zentralen implantierten Katheter wie für andere Medikamente dieser Klasse benötigt verabreicht werden. FDA ist erforderlich, um eine Aktion Zeitpunkt für die Überprüfung des Antrags 74 Tage nach der ersten Einreichung des Zulassungsantrags werden.  CTI geht davon aus, die Klage Termin für dieses Medikamenten-Kandidaten von der FDA und eine endgültige Entscheidung über Review "-Status am 4. September 2009 erhalten.

Über Cell Therapeutics, Inc.

Mit Hauptsitz in Seattle, CTI ist ein biopharmazeutisches Unternehmen spezialisiert auf die Entwicklung eines integrierten Portfolios onkologischer Produkte für eine erfolgreichere Krebsbehandlung verpflichtet.
Für weitere Informationen, besuchen Sie bitte www.celltherapeutics.com/.

Melden Sie sich für E-Mail-Benachrichtigung und nutzen Sie RSS-Feeds auf unserer Webseite, www.celltherapeutics.com/investors_news.htm

Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die eine Reihe von Risiken und Unsicherheiten beinhalten, können die Ergebnisse, die wesentlich und / oder nachteilig auf tatsächliche zukünftige Ergebnisse und der Kurs der Wertpapiere.  Zu den Risiken und Unwägbarkeiten, die die Entwicklung von Pixantrone gehören Risiken in Verbindung mit den vorklinischen und klinischen Entwicklungen in der biopharmazeutischen Industrie im Allgemeinen, und mit Pixantrone insbesondere, einschließlich und ohne Einschränkung zu beeinträchtigen, das eventuelle Scheitern von Pixantrone als sichere und effektive ( auch das Versäumnis, die Gesamt-Ansprechrate, kompletter Remissionen und das progressionsfreie Überleben und die Möglichkeit eines signifikanten Grad 3 / 4 Nebenwirkungen, einschließlich Herzerkrankungen zu erreichen) für die Behandlung von rezidivierenden oder refraktären aggressiven NHL, wie von der FDA, bestimmt das Potenzial dass die FDA nicht akzeptiert, auf die NDA für Pixantrone-Datei, das Potenzial, dass die FDA gewährt keine Priority-Review "-Status für Pixantrone die Möglichkeit, dass eine Entscheidung der FDA ist nicht an 4. September 2009 geleistet, und die Möglichkeit, dass die FDA nicht abnimmt, die NDA für Pixantrone und / oder erfordert zusätzliche klinische Studien mit Bezug auf Pixantrone abgeschlossen werden, CTI Fähigkeit, auch weiterhin bei der Kapitalbeschaffung wie notwendig, um ihre Geschäfte zu finanzieren, Wettbewerbsfaktoren, technologische Entwicklungen, Kosten für die Entwicklung, Herstellung und Verkauf Pixantrone und die Risikofaktoren, wie sie von Zeit zu Zeit in den Einreichungen von CTI bei der Securities and Exchange Commission, einschließlich, ohne Einschränkung, CTI neuesten Einreichungen auf den Formularen 10-K, 10-Q und 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise. Es sei denn dies ist gesetzlich vorgeschrieben, CTI hat nicht die Absicht zu aktualisieren oder zu ändern, ihre Zukunft gerichtete Aussagen, ob als Ergebnis neuer Informationen, zukünftiger Ereignisse oder anderweitig.

Kontakt für die Medien: Dan Eramian T: 206.272.4343 C: 206.854.1200 E: www.celltherapeutics.com/media.htm

Investoren Kontakt: Ed Bell T: 206.282.7100 Lindsey Jesch T: 206.272.4347 F: 206.272.4434 E: www.celltherapeutics.com/investors

Medizinische Informationssysteme Kontakt: T: 800.715.0944 E:

DataSource: Cell Therapeutics, Inc.

KONTAKT: Medien, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,

oder Investoren, Ed Bell, +1-206-282-7100, oder Lindsey

Jesch, +1-206-272-4347, fax, +1-206-272-4434, , alle von

Cell Therapeutics, Inc., oder medizinische Informationen, 1-800-715-0944,

Web-Site: www.celltherapeutics.com/

So Leute, die Party kann beginnen!!!

Let's rock!!!

wallw

Auf lange Sicht bestimmt ein interessantes Investment... aber ein bisschen Geduld wird man schon haben müssen... :-) es sei denn, man ist schon bei 0,05 eingestiegen und hat schon fette Gewinne gemacht...


wallw

SEATTLE, Sept. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). Pixantrone has fast track designation for the relapsed / refractory aggressive NHL application

www.pharmalive.com/News/...?articleid=649547&categoryid=51

...bist du etwa davon ausgegangen, dass am 04.September die FDA-Zulassung gegeben wird ??

Am 04.September wurde nichts anderes gemacht als das entgültige Datum für/gegen eine Pixatrone-Zulassung festzulegen! Die Unterlagen dazu wurden durch CTIC  schon am 24.August an die FDA eingereicht etc... .

siehe Auszug ==>

On 8/24/09, according to a 8K SEC filing, the FDA accepted the NDA and indicated a standard review (10-month) for pixantrone which the Company appealed since it requested a priority (six-month) review. On 9/5/09, CTIC announced that the FDA established a PDUFA action date of 4/23/10 (representing a standard, 10-month review designation) for pixantrone as a potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTIC estimates that pixantrone could be available to patients in the U.S. during early 2Q10 if approved by the FDA

__________________________________________________

...Leute, bevor Ihr kauft bzw. verkauft - erstmal über die Aktie, welche ihr kauft/verkauft INFORMIEREN!!!

__________________________________________________

FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
 
    * Press Release
    * Source: Cell Therapeutics, Inc.
    * On Saturday September 5, 2009, 1:30 am EDT
 
http://finance.yahoo.com/news/...-prnews-3677779837.html?x=0&.v=1
 
SEATTLE, Sept. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). Pixantrone has fast track designation for the relapsed / refractory aggressive NHL application.
 
"The 18 month follow up PIX 301 pivotal trial data continues to demonstrate further improvement in primary and secondary endpoints including Complete Remission / Complete Remission unconfirmed(CR/CRu), Progression Free Survival (PFS) and Overall Survival over standard chemotherapy. We look forward to providing the four month safety and efficacy update to the FDA and working with them toward potential approval," said James A. Bianco, M.D., Chief Executive Officer of CTI.
 
Based on the user fee goal date, if pixantrone is approved, CTI estimates that pixantrone could be available to patients in the U.S. early in the second quarter of 2010.
 
About Pixantrone
 
Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns.
 
About Fast Track
 
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially superior to existing therapy.
 
__________________________________________________
 
About Pixantrone
 
Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from currently marketed anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although anthracyclines are sufficiently effective to be used as first-line (initial) treatment, anthracyclines cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if the patient's disease returns. Pixantrone also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. The FDA is required to set an action date for review of an application 74 days after the initial submission of the NDA.
 
CTI expects to receive the action date for this drug candidate from the FDA and a final decision on review status on September 4th, 2009.

nein das hatte ich nicht, wollte nur diese INfo weitergeben...
Aber mittlerweile weiß ich auch, dass selbst der April nicht unbedingt sein muss!
Siehe zb Hemispherx BioPharma, Inc., da war eine Entscheidung für Mai 09 geplant ;-)

OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Pot
 
Date : 10/01/2009 @ 1:30AM
Source : PR Newswire
Stock : (CTIC)
 
http://ih.advfn.com/...pid=nmona&article=39703457&symbol=CTIC
 
Phase II results to be presented at Proffered Session of International Society of Gastrointestinal Oncology
 
PHILADELPHIA, Oct. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.
 
The phase II study, led by Dr. Safran, enrolled 40 patients with pathologically-confirmed, locally-advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastasis. The patients received weekly paclitaxel poliglumex (50mg/m2) and cisplatin 25mg/m2 for six weeks with concurrent 50.5Gy of radiation. Of the first 28 patients undergoing surgery, all with adenocarcinoma, eight of 28 (28.5%), have achieved a pathologic CR. No patients required a feeding tube, in contrast to historical studies using the standard regimen where the large majority of patients require a feeding tube. There were no grade 4 hematologic toxicities; grade 3 hematologic toxicity included neutropenia (n=2) and anemia (n=1). Four of 35 patients experienced grade 4 non-hematologic toxicities, which included electrolyte abnormalities, glucose intolerance, hypersensitivity reaction and thromboembolus. Eleven of 35 patients had grade 3 non-hematologic toxicities including electrolyte abnormalities (n=5), nausea (n=3), dysphagia (n=2), fatigue (n=2), glucose intolerance (n=2), and hypersensitivity reaction (n=1). Grade 3 anorexia was reported in only one patient who subsequently was given total parenteral nutrition. No patients developed neuropathy.
 
"These are very promising results, as standard platinum, 5-FU, and radiation-based regimens for this disease are accompanied by a high incidence of severe radiation esophagitis, requiring patients to receive nutrition through feeding tubes," said Dr. Safran. "Paclitaxel poliglumex's selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission and low rates of severe regional side effects we have observed in this phase 2 study. Our results justify proceeding to a randomized, controlled trial to definitively prove the impressive clinical benefit we have observed in our experience with this novel bioengineered paclitaxel agent," Dr. Safran added.
 
"We look forward to discussing with the Food and Drug Administration a potential phase III registration strategy for this indication," said Jack Singer, M.D., Chief Medical Officer at CTI. "This would be the first registration study for a radiation sensitizing agent in this indication."
 
Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, which is a regimen associated with a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4-fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int'l J. Radiat. Oncol. Biol. Phys. 55(3), 707-12 (2003)).
 
The presentation slides are available at http://www.celltherapeutics.com/investor_updates.
 
CTI has an existing license and co-development agreement with Novartis for OPAXIO, which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.
 
About OPAXIO(TM)
 
OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.
 
About Cell Therapeutics, Inc.
 
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
 
Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_news.htm
 
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential for OPAXIO to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that OPAXIO will not produce high rates of complete remission in patients with advanced esophageal cancer, the possibility that the registration trial for OPAXIO as a radiation sensitizer will not occur, the possibility that the U.S. Food and Drug Administration will not approve a phase III registration strategy for paclitaxel poliglumex if proposed by CTI, the potential that Novartis will not exercise its option, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and selling OPAXIO. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
 
Media Contact:
 
Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room
 
Investors Contact:
 
Ed Bell T: 206.282.7100 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors
 
Medical Information Contact:
 
T: 800.715.0944 E:
 
DATASOURCE: Cell Therapeutics, Inc.
 
CONTACT: Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
 
, or investors, Ed Bell, +1-206-282-7100, or Lindsey
 
Jesch Logan, +1-206-272-4347, fax, +1-206-272-4434, , all
 
of Cell Therapeutics, Inc.; or Medical Information, 1-800-715-0944,
 
Web Site: http://www.celltherapeutics.com/

 

 

www.shortsqueeze.com/?symbol=ctic&submit=Short+Quote%99

Short Interest (Shares Short)
          §38,353,500
Days To Cover (Short Interest Ratio)
          §1.5
Short Percent of Float
          §7.28 %

translate.google.de/...amp;sl=en&tl=de&history_state0=

translate.google.de/...amp;sl=en&tl=de&history_state0=

translate.google.de/...1116%2Fctic8-k.html&sl=en&tl=de

zu cell...?
Also durch dieses Formular 8-K bin ich nicht schlauer geworden.
Kann mir jemand sagen wie es um die Aktien steht?

translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de

translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de

translate.google.de/...1124%2Fctic8-k.html&sl=en&tl=de

www.rttnews.com/ArticleView.aspx?Id=1142198

Cell Therapeutics Says Bis-platinates Showed Stronger Anti-tumor Potency And Activity Than Platinum-based Compounds - Update
11/30/2009 2:02 AM ET


RELATED NEWS
          §
Cell Therapeutics Says Its Bis-platinates Showed Stronger Anti-tumor Potency And Activity - Quick Facts
          §
Cell Therapeutics Wins Federal Appeal To Pursue $22.8 Mln Claim Against Lash Group - Quick Facts
          §
Cell Therapeutics Q3 09 Earnings Conference Call At 8:30 AM
          §
Cell Therapeutics Posts Wider Loss In Q3 - Update
          §
Cell Therapeutics Q3 Net Loss Widens - Quick Facts
(RTTNews) - Biopharmaceutical company Cell Therapeutics, Inc. (CTIC: News ) said Monday that its new class of platinum-based anti-tumor compounds, called bis-platinates, demonstrated a stronger anti-tumor potency and activity, compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

The Seattle, Washington-based company noted that platinum-based compounds, such as cisplatin and oxaliplatin, have a pivotal role in the treatment of testicular, ovarian, colorectal and lung cancers. However, their effectiveness is restricted by the low therapeutic ratio, ratio of the maximally tolerated dose of the drug to the effective dose, and the frequent occurrence of drug resistance. The novel bis-platinum compounds represent a completely new class of platinum-based drugs called bisplatinates, Cell Therapeutics added.

Unlike platinum-based compounds, the bis-platinum based compounds contain two platinum atoms and work by binding to and damaging both strands of DNA. This makes it much more difficult for cancer cells to repair the damage. The research demonstrated through cancer cell assays and animal tumor models that the bis-platinum complexes showed greater cytotoxic potency and anti-tumor effect, compared to cisplatin and oxaliplatin.

According to the company, there was more than a 200-fold increase in percent accumulation in tumor cells of the bisplatinum compounds, compared to cisplatin and oxaliplatin. The bisplatinates were substantially more active against human tumors grown in an immunodeficient preclinical model than the standard palatinate compounds, oxaliplatin, carboplatin and cisplatin, Cell Therapeutics added.

Additionally, the bis-platinum compounds demonstrated the ability to overcome tumor resistance to cisplatin mediated by DNA mismatch repair defects. The complexes showed marked anti-tumor efficacy in platinum refractory tumors, with significant activity in terms of tumor growth inhibition and tumor growth delay.

translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de

translate.google.de/...1130%2Fctic8-k.html&sl=en&tl=de

auf der 51. Jahrestagung der American Society of Hematology präsentiert

Unternehmen, Investoren und Analysten Host-Sitzung am 5. Dezember 2009

translate.google.de/...ml%3Fx%3D0%26.v%3D1&sl=en&tl=de

Bin mal gespannt wie die Amerikaner auf die neuen Studienergebnisse reagieren